PAK1 and cancer: Lastly, although many studies have indicated the potential benefits of targeting group I PAKs (PAK1‐3) for cancer therapy (Al‐Azayzih et al., 2015; Kichina et al., 2010; Rudolph et al., 2013; Semenova & Chernoff, 2017; Somanath et al., 2023; Verma, Artham, et al., 2020; Verma, Najahi‐Missaoui, et al., 2020), clinical validation of other PAK isoforms as therapeutic targets is needed to confirm their potential in cancer treatment.